Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy

Lyons, Bayard; Austin, Daniel; Seelye, Adriana; Petersen, Jóhanna; Yeargers, Jonathan; Riley, Thomas; Sharma, Nicole; Mattek, Nora; Dodge, Hiroko H.; Wild, Katherine; Kaye, Jeffrey

doi:10.3389/fnagi.2015.00232

Cited by 63 publications

(71 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The revolution in mobile technologies such as smart phones/ tablets, cloud-based platforms, and deep learning-driven software algorithms and miniaturized automated physiological sensors is poised to profoundly disrupt medicine [3][4][5][6][7] and, by extension, many aspects of neuropsychiatry and AD care and clinical research. [5][6][7][8] In this Perspective, we highlight four areas in which such technology could facilitate AD clinical trials: (1) Mobilizing recruitment, (2) Mobile cognitive measures, (3) Digital functional outcomes, and (4) Integrated informatics platforms.…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7][8] In this Perspective, we highlight four areas in which such technology could facilitate AD clinical trials: (1) Mobilizing recruitment, (2) Mobile cognitive measures, (3) Digital functional outcomes, and (4) Integrated informatics platforms. For further information on how technology may help with care and caregiver support, readers are referred elsewhere.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials

2018

View full text Add to dashboard Cite

The rapid growth of mobile phones, automated speech recognizing personal assistants, and internet access among the elderly provides new opportunities for incorporating such technologies into clinical research and personalized medical care. Alzheimer's disease is a good test case given the need for early detection, the high rate of clinical trial failures, the need to more efficiently recruit patients for trials, and the need for sensitive and ecologically valid trial outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials

2018

View full text Add to dashboard Cite

show abstract

“…Therefore, AD and PD associated behaviours clearly indicate that long before the identification of typical neurological manifestations of these diseases, patients start manifesting behavioural changes [145]. So, monitoring such typical patterns of behavioural changes can help in early diagnosis of these diseases.…”

Section: Necessity Of Behavioural Typing For Neurological Disease Diamentioning

confidence: 99%

“…Such patients also have a prevalence of pathologic hypersexuality as well as repetitive reward seeking behaviour. Furthermore, research suggests that significant percentage of people with Rapid Eye Movement (REM) sleep behaviour disorder (RBD) suffer from Parkinson's disease [145].…”

Section: Necessity Of Behavioural Typing For Neurological Disease Diamentioning

confidence: 99%

Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

Choudhury¹,

Sahu²,

Ramanujam³

et al. 2018

Neuropsychiatry

View full text Add to dashboard Cite

Structural changes in different regions of the brain have become clinically relevant and regarded as the signature phenomenon for neurological diseases. Morphological changes in brain are also associated with neuronal and neurochemical alterations. Studies have showed that minute changes in neurochemical levels may have marked impact on the psychobehaviour of the subject. Several neurological disease profiles have been reported with such specific psychobehavioural expression. However, application of behavioural abnormalities as possible disease progress markers has not been considered and emphasised much. Reports suggested that-the subjects, who have already entered into the terminal stage of the disease, used to show cardinal behavioural signs for a specific disease profile. However, psychological expressions are comparatively early expressive. As most of the neurodegenerative disorders are unidirectional and progressive by nature, therapeutic intervention at the right time is essential for attaining the desired outcome. Moreover, early diagnosis can aid in managing the disease progression also. Psychobehavioural analysis could meet the expected outcome of disease diagnosis if implemented properly and timely. In the present review, we have amalgamated the reported behavioural anomalies with the supportive background from neurochemical basis. Further, we have concluded that behaviour centric studies could be a potential diagnostic tool for the early diagnosis of major neurological diseases such as Alzheimer disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), Bipolar disorder, Schizophrenia, Impulse control disorder (ICD) and Obsessive-compulsive disorder (OCD).

show abstract

“…Home-based, pervasive sensing and computing systems provide a novel method to capture data on metrics related to everyday physical and cognitive function [17]. The EVALUATE-AD (Ecologically Valid, Ambient, Longitudinal and Unbiased Assessment of Treatment Efficacy in Alzheimer’s Disease) study is an observational proof-of-concept trial examining the feasibility of using an unobtrusive home-based monitoring system to detect the effects of initiating or discontinuing standard dementia treatments.…”

Section: Introductionmentioning

confidence: 99%

EVALUATE-AD and Tele-STAR: Novel Methodologies for Assessment of Caregiver Burden in a Telehealth Caregiver Intervention – A Case Study

Thomas

Lindauer

Kaye

2019

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Aims: We explored the relationship between objective and subjective measures of burden prior to and after a telehealth-based caregiver intervention. One caregiver participated in two studies, one to assess the feasibility of objective, home-based monitoring (EVALUATE-AD), the second to assess the feasibility of a caregiver education telehealth-based intervention, Tele-STAR. Methods: Subjective measures of burden and depression in Tele-STAR and objective measures related to daily activities of the caregiver in EVALUATE-AD were compared to examine trends between the different outcome measures. Results: While the caregiver reported an increase in distressing behaviors by her partner, burden levels did not significantly change during or after the Tele-STAR intervention, while objective measures of activity and sleep showed a slight decline. Conclusion: Unobtrusive home-based monitoring may provide a novel, objective method to assess the effectiveness of caregiver intervention programs.

show abstract

Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy

Cited by 63 publications

References 0 publications

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials

Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

EVALUATE-AD and Tele-STAR: Novel Methodologies for Assessment of Caregiver Burden in a Telehealth Caregiver Intervention – A Case Study

Contact Info

Product

Resources

About